SS
LCTX icon

Sunbelt Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

Sunbelt Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.16K Buy
+2,000
New +$3.37K ﹤0.01% 1807

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sunbelt Securities's LCTX Position: Q1 2026 in Review

Sunbelt Securities opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2026: 2,000 shares worth $3.16K. The stake represents ﹤0.01% of the portfolio and ranks #1807 among its holdings.

130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Sunbelt Securities held 2,000 shares of Lineage Cell Therapeutics worth $3.16K as of Q1 2026.
  • Lineage Cell Therapeutics was a new Sunbelt Securities position in Q1 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #1807 holding.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.